Concepedia

Sharan K. Bagal

SK

20

Publications

987

Citations

18

H-Index

2009

Active since

Affiliations

Pfizer (United Kingdom)(Current)

Pfizer (United States)

AstraZeneca (United States)

AstraZeneca (United Kingdom)

AstraZeneca (Sweden)

Sharan K. Bagal is an author at Pfizer (United Kingdom) specializing in drug discovery, medicine, and pharmacology.

ORCID

Top concepts

Publications per year

2009–2024

20

Publications

20

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Jessie Hao-Ru Hsu, Timothy Rasmusson, James Robinson et al. · Cell chemical biology · 2019 · 192 citations · Full text

, ,

A novel selective and orally bioavailable <scp>N</scp> a <scp> <sub>v</sub> </scp> 1.8 channel blocker, <scp>PF</scp> ‐01247324, attenuates nociception and sensory neuron excitability

C. Elizabeth Payne, Adam R. Brown, Jonathon W Theile et al. · British Journal of Pharmacology · 2015 · 96 citations · Full text

The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain

S. Skerratt, Mark D. Andrews, Sharan K. Bagal et al. · Journal of Medicinal Chemistry · 2016 · 80 citations · Full text

, , +21

Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS<sup>G12C</sup>

Jason G. Kettle, Sharan K. Bagal, Sue Bickerton et al. · Journal of Medicinal Chemistry · 2020 · 80 citations · Full text

Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS<sup>G12C</sup>

Jason G. Kettle, Sharan K. Bagal, Sue Bickerton et al. · Journal of Medicinal Chemistry · 2022 · 56 citations · Full text

Rows per page

1–5 of 20